Preclinical assessment of Alzheimer's disease using novel designed 99mTc‐labeled RGD‐based pro‐apoptotic cyclic peptide as a promising SPECT agent

Table S1 RGD-based antimicrobial peptide analogs used in this study

Table S2 Comparison of percent labeling efficiency using SnCl2.2H2O and NaBH4 as reducing agents (n = 3, ± SD)

Table S3 Biodistribution pattern of 99mTc-DTPA in Alzheimer's disease induced Balb/c mice models

Figure S1 Qualitative analysis of pure peptides (a) cyclic peptide, (b) linear peptide, and DTPA-peptide analogs (c) DTPA-cPT and (d) DTPA-LPT complexes using HPLC technique.

Figure S2 HR-MS spectrogram of DTPA-peptide conjugates (a) for DTPA-cPT and (b) for DTPA-LPT analogs.

Figure S3 FTIR-ATR spectrograms of diethylenetriamine pentaacetic acid cyclic bis (anhydride) (cDTPA, black line), DTPA conjugated cyclic peptide (DTPA-cPT, red line), and DTPA conjugated linear peptide (DTPA-LPT, blue line) complexes indicating no observable change during the synthesis process.

Figure S4 Radiochromatograms show percent radiochemical purity calculated by Radio-HPLC analysis for (a) free pertechnetate [99mTcO4−] and (b) 99mTc-tricarbonyl [99mTc(CO)3(H2O)3]+ precursor

Figure S5 LAT accumulation in rabbit's brain tissues causes neurological disorders confirmed by (a) Hematological analysis, (b) Serum electrolyte analysis, (c) indicates concentration of LAT in rabbit's blood and brain tissue samples, (d) shows biochemical analysis, while (e) represents the histological evaluation of brain tissues. (p < 0.05, n = 3)

Figure S6 In vivo assessment of metabolic stability of 99mTc(CO)3DTPA-cPT complex prepared as lyophilized kit and injected in animal. The radiochromatograms show peaks of intact radiotracer in (a) Blood, (b) Urine, (c) Kidneys, and (d) Liver samples.

Figure S7 SPECT images presenting time-dependent accumulation of novel designed radiotracer in AD-induced brain area acquired from different positions in rabbit models.

留言 (0)

沒有登入
gif